Rhenium-188-HEDP

Rhenium-188-HEDP (also known as Rhenium-188-hydroxyethylidene diphosphonate) is a radiopharmaceutical used primarily for the palliative treatment of painful bone metastases. It's a beta-emitting agent that localizes in areas of increased bone turnover, particularly in osteoblastic skeletal metastases. ## Composition and Properties Rhenium-188-HEDP consists of the radioisotope rhenium-188 (Re-188) labeled with hydroxyethylidene diphosphonate (HEDP). Re-188 has a short physical half-life of 16.9 hours and emits high-energy beta particles with a maximum energy of 2.1 MeV[2][4]. This makes it therapeutically useful for treating bone metastases while minimizing radiation exposure to surrounding tissues. The radiopharmaceutical is chemically similar to the previously commercially available 186Re-HEDP (Re-Bone®), with the difference being that it uses the rhenium-188 isotope instead[8]. ## Mechanism of Action After intravenous administration, Rhenium-188-HEDP is rapidly taken up by bone, with preferential accumulation in bone metastases, achieving a high metastasis-to-normal bone ratio[8]. The compound is primarily excreted through the kidneys[8]. The therapeutic effect comes from the beta radiation emitted by rhenium-188, which delivers localized radiation to bone metastases, helping to relieve pain. An important aspect of preparing Rhenium-188-HEDP is the need to decrease specific activity by adding "cold" rhenium (carrier) to achieve good bone fixation[2]. ## Clinical Applications Rhenium-188-HEDP is primarily used for: - Palliative treatment of painful osteoblastic skeletal metastases, particularly from prostate cancer - Treatment of bone metastases from various other primary cancers including lung, breast, renal, rhinopharyngeal, and bladder cancers - Pain management in patients who have experienced recurrent pain following local radiotherapy[8] ## Clinical Efficacy Multiple clinical studies have demonstrated the effectiveness of Rhenium-188-HEDP: - A large clinical trial with 61 patients showed prompt and significant relief of bone pain in 80% of patients overall, with pain relief achieved in 77% of lung cancer patients, 80% of prostate cancer patients, 83% of breast cancer patients, and 100% of bladder cancer patients[5][7]. - A controlled, randomized, double-blind clinical trial comparing Rhenium-188-HEDP plus analgesic management versus analgesic management plus placebo showed lower levels of pain in the intervention group, especially during the first follow-up month[3]. - A study of 27 prostate cancer patients treated with Rhenium-188-HEDP showed improvement on the Karnofsky performance scale from 74±7% to 85±9% after 12 weeks of therapy. 76% of patients described pain relief without increased analgesic intake, and 20% were able to discontinue analgesics completely and became pain-free[6]. ## Safety Profile Rhenium-188-HEDP has shown minimal bone marrow toxicity in clinical studies. In one study, mean platelet count decreased from (286±75)×10³/μl to (215±92)×10³/μl, and mean leucocyte count from (7.7±1.5)×10³/μl to (6.0±1.9)×10³/μl in the second to fourth week after therapy, but these changes were not statistically significant[6]. Contraindications include thrombocyte levels <100×10⁹/l, leucocyte levels <3.0×10⁹/l, continued breast-feeding, pain with neurological deficit due to metastatic invasion, and pregnancy[8]. ## Advantages Rhenium-188-HEDP offers several advantages as a radiopharmaceutical: - It can be produced from a tungsten-188/rhenium-188 generator, making it convenient for clinical therapeutic use - Its short half-life (16.9 hours) minimizes prolonged radiation exposure - It has shown efficacy in treating painful bone metastases from various tumor types - It demonstrates minimal hematopoietic toxicity Rhenium-188-HEDP represents an effective option for palliative treatment of metastatic bone pain, particularly in patients with prostate cancer and other malignancies with skeletal spread.

Other names

Rhenium-188-hydroxyethylidene diphosphonateRhenium188-hydroxyethylidene diphosphonateRhenium 188-hydroxyethylidene diphosphonate